Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms GEMELLI 1
- Sponsors Sanofi
- 08 Dec 2017 Planned number of patients changed from 500 to 800.
- 02 Aug 2017 Status changed from not yet recruiting to recruiting.
- 10 Jul 2017 New trial record